As of July 2017, bromocriptine was marketed under many brand names worldwide, including Abergin, Barlolin, Brameston, Brocriptin, Brom, Broma-Del, Bromergocryptine, Bromergon, Bromicon, Bromocorn, Bromocriptin, Bromocriptina, Bromocriptine, Bromocriptine mesilate, Bromocriptine mesylate, Bromocriptine methanesulfonate, Bromocriptini mesilas, Bromocriptinmesilat, Bromodel, Bromokriptin, Bromolac, Bromotine, Bromtine, Brotin, Butin, Corpadel, Cripsa, Criptine, Criten, Cycloset, Degala, Demil, Deparo, Deprolac, Diacriptin, Dopagon, Erenant, Grifocriptina, Gynodel, kirim, Kriptonal, Lactodel, Medocriptine, Melen, Padoparine, Palolactin, Parlodel, Pravidel, Proctinal, Ronalin, Semi-Brom, Serocriptin, Serocryptin, Suplac, Syntocriptine, Umprel, Unew, Updopa, Upnol B, and Volbro. 
Bromocriptine should be withdrawn when pregnancy is diagnosed whenever possible, unless a rapidly expanding macroadenoma necessitates continued use. In patients being treated for acromegaly, prolactinoma, diabetes mellitus, or Parkinson's disease, consider the medical necessity of bromocriptine or if the therapy can be withdrawn. If a patient continuing bromocriptine during pregnancy experiences a hypertensive disorder of pregnancy (including preeclampsia, eclampsia, or pregnancy-induced hypertension), the benefit of continuing the drug must be weighed against cardiovascular risks. In making the decision to administer bromocriptine during pregnancy, the potential risks to the fetus must be weighed against the potential maternal benefits, which are dependent on the initial indication for use. From a teratogenic perspective, bromocriptine is classified as FDA pregnancy risk category B. Although no adequate human studies have been performed on the effects of this drug on the fetus, data concerning 1276 pregnancies in women taking bromocriptine are available. In the majority of cases, bromocriptine was discontinued within 8 weeks into pregnancy (mean days); however, 8 patients received the drug continuously throughout pregnancy. The mean daily dose for all patients was mg (range 1—40 mg). After delivery, the drug is also contraindicated in the post-partum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If bromocriptine (Parlodel) is used in the post-partum period, the patient should be observed with caution.
Patients should be informed of the potential risks and benefits of CYCLOSET and of alternative therapies. Patients should also be informed about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1c testing, recognition and management of hypoglycemia and hyperglycemia , and assessment for diabetes complications . During periods of stress such as fever , trauma , infection, or surgery, medication requirements may change and patients should be advised to seek medical advice promptly.